{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-035590","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.225272+00:00","generated_at":"2026-06-17T21:27:26.693900+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Record FY2022 revenue $49.2M; FDA delays CanGaroo RM; Q4 net loss narrows","bullets":["FY2022 net sales $49.2M (+4% YoY); ex-discontinued FiberCel, current product sales up 16%.","Q4 net sales $12.7M (+17% YoY); CanGaroo and SimpliDerm combined grew 30%.","FDA delayed clearance of CanGaroo RM Antibacterial Envelope; company cutting costs to extend cash runway.","Q4 gross margin improved to 39% (non-GAAP 46%); net loss per share $0.38 vs $0.82 YoY.","Entered U.S. distribution agreement with Sientra for SimpliDerm; cash $17.0M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-035590","json":"https://secwatch.observer/filing/0001104659-23-035590.json","markdown":"https://secwatch.observer/filing/0001104659-23-035590.md","text":"https://secwatch.observer/filing/0001104659-23-035590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923035590/0001104659-23-035590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923035590/tm2310291d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:27:26.693900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"092f2572a6d5d67f62ae85e1ac7b8b48fa57ec12","claim":"ELUTIA INC. reported the fourth quarter ended December 31, 2022 results: revenue $12.7 million, net income Net loss was $5.4 million, EPS Net loss per share in the fourth quarter of 2022 was $0.38 per share.","evidence_excerpt":"Net sales for the fourth quarter of 2022 were $12.7 million, an increase of 17% compared to the fourth quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923035590/0001104659-23-035590-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$12.7 million"},{"label":"Net income","value":"Net loss was $5.4 million"},{"label":"EPS","value":"Net loss per share in the fourth quarter of 2022 was $0.38 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d8e7d85dcf8d43b7d3c4681d1b007cac7817b37b","claim":"ELUTIA INC. reported the full year ended December 31, 2022 results: revenue $49.2 million, net income Net loss was $32.9 million, EPS Loss per share in the full year 2022 was $2.38 per share.","evidence_excerpt":"Net sales for the full year 2022 were $49.2 million, an increase of 4% compared to the full year 2021 net sales of $47.4 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923035590/0001104659-23-035590-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Revenue","value":"$49.2 million"},{"label":"Net income","value":"Net loss was $32.9 million"},{"label":"EPS","value":"Loss per share in the full year 2022 was $2.38 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}